MyoKardia, Inc. (MYOK) financial statements (2020 and earlier)

Company profile

Business Address 333 ALLERTON AVENUE
SOUTH SAN FRANCISCO, CA 94080
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments416315257140112
Cash and cash equivalents101246225136112
Short-term investments31569324 
Restricted cash and investments0    
Other undisclosed current assets753461
Total current assets:424319259186114
Noncurrent Assets
Operating lease, right-of-use asset0
Property, plant and equipment165333
Long-term investments and receivables14802012 
Long-term investments14802012 
Restricted cash and investments22   
Other noncurrent assets  000
Other undisclosed noncurrent assets00   
Total noncurrent assets:328823153
TOTAL ASSETS:456407283201117
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities482414108
Accounts payable63222
Accrued liabilities41211296
Debt0    
Deferred revenue and credits232314
Other undisclosed current liabilities 134  
Total current liabilities:4837413322
Noncurrent Liabilities
Liabilities, other than long-term debt200231
Deferred revenue and credits 23 
Other liabilities20001
Total noncurrent liabilities:200231
Total liabilities:5037415623
Stockholders' equity
Stockholders' equity attributable to parent40637124214594
Common stock00000
Additional paid in capital884573366223159
Accumulated other comprehensive income (loss)1(0)(0)0 
Accumulated deficit(479)(203)(124)(78)(65)
Total stockholders' equity:40637124214594
TOTAL LIABILITIES AND EQUITY:456407283201117

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Gross profit: 34   
Operating expenses(288)(107)(70)(53)(37)
Other undisclosed operating income  233914
Operating loss:(288)(74)(48)(13)(23)
Loss before gain (loss) on sale of properties:(288)(74)(48)(13)(23)
Other undisclosed net income126   
Net loss:(276)(68)(48)(13)(23)
Other undisclosed net income attributable to parent  200
Net loss attributable to parent:(276)(68)(46)(13)(23)
Preferred stock dividends and other adjustments    (5)
Net loss available to common stockholders, diluted:(276)(68)(46)(13)(28)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(276)(68)(48)(13)(23)
Other comprehensive income (loss)10(0)0 
Comprehensive loss:(276)(68)(48)(13)(23)
Other undisclosed comprehensive income, net of tax, attributable to parent  20 
Comprehensive loss, net of tax, attributable to parent:(276)(68)(46)(13)(23)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: